GlaxoSmithKline Pakistan Statistics

Total Valuation

GlaxoSmithKline Pakistan has a market cap or net worth of PKR 127.38 billion. The enterprise value is 120.85 billion.

Market Cap	127.38B
Enterprise Value	120.85B

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

GlaxoSmithKline Pakistan has 318.47 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	318.47M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	5.64%
Float	318.25M

Valuation Ratios

The trailing PE ratio is 28.26.

PE Ratio	28.26
Forward PE	n/a
PS Ratio	2.27
PB Ratio	5.04
P/TBV Ratio	5.24
P/FCF Ratio	29.71
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.51, with an EV/FCF ratio of 28.19.

EV / Earnings	26.82
EV / Sales	2.15
EV / EBITDA	14.51
EV / EBIT	16.69
EV / FCF	28.19

Financial Position

The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.01.

Current Ratio	1.68
Quick Ratio	0.82
Debt / Equity	0.01
Debt / EBITDA	0.02
Debt / FCF	0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 19.63% and return on invested capital (ROIC) is 19.63%.

Return on Equity (ROE)	19.63%
Return on Assets (ROA)	10.48%
Return on Capital (ROIC)	19.63%
Revenue Per Employee	33.08M
Profits Per Employee	2.65M
Employee Count	1,700
Asset Turnover	1.30
Inventory Turnover	3.12

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +383.82% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+383.82%
50-Day Moving Average	326.35
200-Day Moving Average	183.03
Relative Strength Index (RSI)	52.04
Average Volume (20 Days)	686,322

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GlaxoSmithKline Pakistan had revenue of PKR 56.23 billion and earned 4.51 billion in profits. Earnings per share was 14.15.

Revenue	56.23B
Gross Profit	10.33B
Operating Income	7.24B
Pretax Income	7.52B
Net Income	4.51B
EBITDA	8.31B
EBIT	7.24B
Earnings Per Share (EPS)	14.15

Full Income Statement

Balance Sheet

The company has 6.69 billion in cash and 168.01 million in debt, giving a net cash position of 6.53 billion or 20.49 per share.

Cash & Cash Equivalents	6.69B
Total Debt	168.01M
Net Cash	6.53B
Net Cash Per Share	20.49
Equity (Book Value)	25.26B
Book Value Per Share	79.29
Working Capital	13.73B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.50 billion and capital expenditures -2.21 billion, giving a free cash flow of 4.29 billion.

Operating Cash Flow	6.50B
Capital Expenditures	-2.21B
Free Cash Flow	4.29B
FCF Per Share	13.46

Full Cash Flow Statement

Margins

Gross margin is 18.38%, with operating and profit margins of 12.88% and 8.01%.

Gross Margin	18.38%
Operating Margin	12.88%
Pretax Margin	13.38%
Profit Margin	8.01%
EBITDA Margin	14.78%
EBIT Margin	12.88%
FCF Margin	7.62%

Dividends & Yields

GlaxoSmithKline Pakistan does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	40.90%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	3.54%
FCF Yield	3.37%

Dividend Details

Stock Splits

The last stock split was on April 18, 2014. It was a forward split with a ratio of 1.1.

Last Split Date	Apr 18, 2014
Split Type	Forward
Split Ratio	1.1

Scores

GlaxoSmithKline Pakistan has an Altman Z-Score of 3.61.

Altman Z-Score	3.61
Piotroski F-Score	n/a